July 3, 2008Adolor Provides Update on Entereg(R) (alvimopan) OBD Program - Forbes Adolor Provides Update on Entereg(R) (alvimopan) OBD Program - Forbes
Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S. Food and Drug Administration Source: www.forbes.com # posted by Network @ 6:03 AM
 |
Subscribe to Posts [Atom]